Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

The Real Reason Sonic Healthcare Shares Jumped 3% Today

Today Sonic Healthcare Ltd (ASX:SHL) released its half-year results to the market for the period ending 31 December 2018, with its net profit up 7%.

The Sonic Healthcare Ltd (ASX: SHL) share price rose 3% today after the healthcare company released its half-year results to the market for the period ending 31 December 2018.

Sonic Healthcare is one of Australia’s largest healthcare businesses, it provides laboratory services, pathology, and radiology services. It is actually the world’s third-largest pathology/laboratory medicine company. It has operations in Australia, USA, Germany, Belgium, Switzerland, the United Kingdom, Ireland and New Zealand.

Key Results

Sonic Healthcare reported:

Management Commentary

Sonic Healthcare has performed well in the half-year, with our US, Swiss and Australian laboratory operations achieving particularly strong earnings growth,” Sonic Healthcare CEO, Dr Colin Goldschmidt, said. “I am especially proud that the revenue of our US business grew 8% organically in the half, which we believe is well above market… We believe there is significant upside to come from both initiatives, and we are working on a number of additional potential hospital laboratory opportunities, as well as pursuing other avenues of organic and acquisitional growth.”

FY19 Guidance Upgraded After Aurora

Probably the most optimistic piece of information from today’s update was that the company bedded down its US acquisition of Aurora Diagnostics back in January 2019 (after the period ended). Mr Goldschmidt described the takeover as, “tremendously exciting”. He attributed the company’s global success to their “Medical leadership culture… [which] recognises that pathologists are the natural leaders within laboratories”.

For its 2019 financial year, Sonic’s management had guided for a 3%-5% increase in underlying EBITDA to $962 million in constant currency. Managemenhasve since revised their forecast to include the Aurora acquisition with growth now expected to be 6-8%, meaning underlying EBITDA could come in between $1.02 billion and $1.04 billion in constant currency.

Rask Perspective

The healthcare sector is an appealing industry to invest in with strong tailwinds. However, Sonic Healthcare is outside of my circle of competence and has a mediocre return on capital, so it is not a stock I am interested in adding to my portfolio. Other shares to add to your watchlist include CSL Ltd (ASX: CSL) and Nanosonics Ltd (ASX: NAN). We covered CSL in more detail in this article.

[ls_content_block id=”14947″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content